Formulation by Ether Injection Method and In-Vitro, In-Vivo Evaluation of Tween 80 Based Metformin Loaded Niosomes: A Smart Strategy in the Drug Delivery System
Abstract
Metformin hydrochloride is one of the first-line oral antidiabetics but because of low oral bioavailability and biological half-life, there is need for formulation of more advanced drug delivery systems for this drug. In this study, niosomes loaded with metformin were formulated by the use of ether injection technique to deliver the drug by controlling the release and increasing its antidiabetic activity. Different formulations (F1-F5) were formulated with varying ratios of Tween 80 to cholesterol and these formulations were evaluated by their calibration curve, drug release study, and in vivo antidiabetic study using alloxan induced diabetic Swiss albino mice. The results of the drug release study show that formulations released varying amounts of the drug depending on the surfactant concentration with formulation F3 releasing maximum drug amount (74.67%) within 120 min. As far as in vivo study is concerned, all formulations significantly decreased blood glucose level in comparison with diabetic control group. From among all the formulations, formulation F2 was found to exhibit maximum glucose lowering activity (63.15%) followed by formulation F1 (62.31%), while standard group with metformin treatment showed decrease in glucose levels (75.70%). The above-mentioned results clearly indicate that MTH loaded niosomes are efficacious in reducing diabetes in a controlled manner but further studies on pharmacokinetics and bioavailability are needed.